A global platform advancing pharmaceutical collaboration, innovation, and exports—powering healthcare and connecting markets worldwide
Novartis India has reported total income of Rs. 98.16 crores during the period ended June 30, 2025
The latest BioE3 policy builds the framework for high-performance biomanufacturing to propel the development and production
This certification validates the plant’s robust capabilities in manufacturing a wide range of sterile dosage forms
Carbamazepine Extended-Release Tablets are indicated for use as an anticonvulsant drug
The inspection was conducted from July 22-25, 2025
RPG Life Sciences has reported total income of Rs. 174.15 crores during the period ended June 30, 2025
This GMP certification for our sterile drug product manufacturing facility, Goa Plant II is a testament to our relentless efforts to supply quality and affordable medicines across geographies
Ibrutinib tablets will be produced at Zydus Lifesciences Ltd (SEZ), Ahmedabad
This collaboration aims to bridge India’s talent and translational gap in this rapidly growing field by equipping professionals with practical expertise in the manufacturing of advanced therapies.
Subscribe To Our Newsletter & Stay Updated
